Revelation Biosciences (NASDAQ:REVB) Stock Price Up 2.4% – Here’s Why

Revelation Biosciences, Inc. (NASDAQ:REVB) shot up 2.4% on Friday . The company traded as high as $0.99 and last traded at $0.9550. 46,605 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 121,422 shares. The stock had previously closed at $0.9326.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Revelation Biosciences in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Revelation Biosciences Trading Up 2.4%

The stock has a market capitalization of $5.65 million, a P/E ratio of -0.03 and a beta of -0.11. The firm’s fifty day moving average is $1.20 and its 200-day moving average is $2.53.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.43). Equities research analysts expect that Revelation Biosciences, Inc. will post -49.33 EPS for the current year.

Hedge Funds Weigh In On Revelation Biosciences

A hedge fund recently raised its stake in Revelation Biosciences stock. Sabby Management LLC lifted its holdings in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) by 214.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 207,051 shares of the company’s stock after purchasing an additional 141,262 shares during the period. Revelation Biosciences accounts for about 0.3% of Sabby Management LLC’s portfolio, making the stock its 16th largest position. Sabby Management LLC owned 1.34% of Revelation Biosciences worth $294,000 as of its most recent SEC filing. 12.80% of the stock is owned by institutional investors.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.